Literature DB >> 17336244

Retroperitoneal lymph node dissection in testicular cancer.

Niels-Erik B Jacobsen1, Richard S Foster, John P Donohue.   

Abstract

With long-term survival in excess of 90% across all stages, testicular cancer has come to represent the model for successful multidisciplinary cancer care. Retroperitoneal lymph node dissection (RPLND) remains an integral component of testis cancer management strategies for both early- and advanced-stage disease. Commensurate with improvements made in clinical staging and in our understanding of the natural history of testis cancer, lymphatic spread, and neuroanatomy, considerable modifications in the technique and template of RPLND have taken place. The morbidity of primary RPLND and postchemotherapy RPLND is low when performed by experienced surgeons. This article reviews the evolution, role, and technique of RPLND in contemporary practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17336244     DOI: 10.1016/j.soc.2006.10.003

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  1 in total

1.  Post-chemotherapy robotic retroperitoneal lymph node dissection (RRPLND) in testicular cancer.

Authors:  Mohamed H Kamel; C Mark Jackson; John T Moore; Samy M Heshmat; Nabil K Bissada
Journal:  J Robot Surg       Date:  2012-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.